Novacyt (FR:ALNOV)
:ALNOV
Want to see FR:ALNOV full AI Analyst Report?
Earnings Data
Report Date
Sep 24, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
―Last Year’s EPS
-0.11Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented clear operational and strategic progress: revenue growth, product launches (LightBench Discover, DPYD), strong gross margin (63%), reduced OpEx and a narrowing of reported losses. Management completed an earnings-accretive acquisition (Southern Cross) and emphasized regulatory strength via IVDR approvals. Material headwinds remain — notably a large non-cash impairment (~GBP 14.4m), exceptional charges (~GBP 16m), reduced cash to GBP 11m at end-March 2026 and ongoing operating losses — but management articulated a clear plan to accelerate top-line growth and reduce cash burn. Highlights and lowlights are balanced: tangible improvements and growth catalysts exist, yet meaningful financial and execution risks persist in the near term.Company Guidance
Revenue Performance
Group revenue of GBP 20.0m for FY2025 exceeded market expectations and represents year-on-year growth of ~GBP 0.8m or +4% when stripping out the Taiwanese divestment.
Improved Gross Profit and Margin
Gross profit rose to GBP 12.6m with a strong blended gross margin of 63%, supported by high-margin PCR/RUO sales (Primer Design gross margin >80%).
Reduction in Operating Costs
Underlying operating expenditure reduced (pro forma Yourgene+Novacyt OpEx down from ~GBP 27.5m to GBP 20.4m); comparable underlying OpEx fell ~4% (~GBP 0.7m) after removing prior-year bad debt distortions.
Smaller EBITDA Loss and Lower Net Loss
EBITDA loss reduced by ~14% to GBP 7.8m year-on-year; loss after tax attributable to owners narrowed substantially to GBP 22.9m from GBP 42.0m in the prior year (approx. 45% improvement).
Instrument and Product Momentum
Successful LightBench Discover launch drove instrument sales growth (management cited 20%+ / instrumentation growth of ~25% to GBP 2.5m). New DPYD assay launch imminent (RUO in May, IVDR-certified version expected mid-year).
Clinical Franchise Strength — NIPT and Geography
Clinical business comprised ~70% of revenue (~GBP 14m); NIPT grew ~10% (~GBP 5m) with new contract wins (e.g., St. George University Hospital, Iceland) and Asia Pac expansion (Asia Pac ~30% of revenue, ~GBP 6m) showing double-digit growth.
Strategic Acquisition — Southern Cross Diagnostics
Acquired Southern Cross (upfront consideration ~USD 8.5m with earn-out potential ~AUD 16.5m over 4 years); business is earnings-accretive, generates north of GBP 6m revenue and has tripled since 2023. Integration reported ~75% complete within ~60% of the timeline.
Regulatory Position — IVDR Approvals
Received IVDR accreditation for the Yourgene QST*R-based assay and emphasized IVDR positioning as a durable competitive/regulatory advantage expected to reduce competitor activity over the next 12–24 months.
FR:ALNOV Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
FR:ALNOV Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 30, 2026 | €0.37 | €0.32 | -13.51% |
Sep 30, 2025 | €0.48 | €0.48 | -1.24% |
Apr 30, 2025 | €0.44 | €0.46 | +4.99% |
Sep 26, 2024 | €0.83 | €0.75 | -9.64% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Novacyt (FR:ALNOV) report earnings?
Novacyt (FR:ALNOV) is schdueled to report earning on Sep 24, 2026, Before Open (Confirmed).
What is Novacyt (FR:ALNOV) earnings time?
Novacyt (FR:ALNOV) earnings time is at Sep 24, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Novacyt stock?
The P/E ratio of Novacyt is N/A.
What is FR:ALNOV EPS forecast?
Currently, no data Available